Boston Scientific's 2027 Trough Is the Whole Story

A cyber hack was the headline, but a share-losing EP franchise and a fading WATCHMAN cycle turned a medtech compounder into a no-growth guide — and the stock has already de-rated.

BSX · Earnings Call · 2026-10-28

A growth company guides to no growth

Boston Scientific spent years as the reliable medtech compounder: grow faster than the market, expand margins, use the multiple. Q3 2026 broke that rhythm. Organic sales rose just 1.5%, adjusted EPS fell 3% to $0.73, and management blamed roughly 300 basis points of the revenue miss and $0.07 of EPS on the cyber incident that shut down manufacturing and shipping for eight business days. That alone would be a bad quarter. The real event was the guide: Q4 organic revenue down 1% to 3%, full-year organic growth around 4%, and a blunt warning that 2027 will be a challenge for both sales and adjusted EPS excluding Penumbra. That is not a normal Boston Scientific statement. In February 2026, Mike Mahoney was still defending the long-range plan with “If we were doing our Investor Day today, we'd get the same numbers. 10% plus '26 to '28...” — Michael Mahoney, Chairman and Chief Executive Officer · 2026-02-04 Nine months later, the company is describing 2027 as the trough and 2028 as the recovery. The stock has already rendered a verdict: down 60.8% from its September 2025 peak of $108.14, down 7% over the last 90 trading days, and 18.4% below its August 2026 high. The price-to-revenue multiple of 3.0x, down 65% year over year, is no longer a premium-compounder multiple. It is a show-me multiple.

We are clearly in the middle of a down cycle which is a short term phenomenon for Boston Scientific that you will see that we predicted in fourth quarter based on our guide in 2027.
Michael F. Mahoney, Chairman and Chief Executive Officer · 2026-10-28

What management stopped saying

The contrast with prior calls is stark. In October 2025, WATCHMAN was “WATCHMAN clearly is a gem for Boston Scientific” — Michael Mahoney, Chairman and Chief Executive Officer · 2025-10-22, and the company was comfortable with a 20% annualized market growth projection over the long-range plan. In July 2026, Mahoney still expected “we expect EP to rebound in second half '27, and we expect to get back to kind of at market or above market growth in EP in '28” — Michael Mahoney, Chairman and Chief Executive Officer · 2026-07-29. By this call, the language had inverted: the U.S. WATCHMAN standalone procedure declined high teens, the global WATCHMAN business fell 7% in the U.S., and management assumed the market stays at roughly -7% to -8% with a competitive launch layered on top in 2027. EP sales fell 5%, U.S. EP fell 8%, and Mahoney conceded “we expect to continue to cede share in 2027 in EP” — Michael F. Mahoney, Chairman and Chief Executive Officer · 2026-10-28 until the next-generation platform arrives. That platform is now late. FARAWAVE Ultra has slipped to early 2028, FARAFLEX to 2029, and 2D ICE to the second half of 2027. The label change that was supposed to help WATCHMAN is now an aspiration for 2028, not a 2027 catalyst. This is why the keyword map has flipped: the company's fresh top themes are now growth profile, early 27, standalone procedure, and WATCHMAN business — defensive language replacing the old offense of PFA leadership and category expansion.

The 75% defense is real, but not enough

Management's best argument is that roughly 75% of the business is still growing about 6% to 7%. Interventional cardiology grew 19%, neuromodulation grew 13%, and the ICBT/vascular complex remains a genuine growth engine. But the drag is concentrated in the two franchises that once supplied the upside: EP and WATCHMAN. Urology fell 3%, endoscopy fell 1%, and China volume-based pricing is now a 2027 headwind rather than a manageable nuisance. The 75% cannot offset the 25% when the 25% is where the margin mix and the narrative lived. The response is a restructuring program targeting more than $500 million of savings over three years, with over half expected to be realized exiting 2027. That is necessary, but it is also a tell: the company is resizing the cost base to a slower-growth reality. Penumbra, the $15 billion-class deal that was supposed to add a new growth vector, is now expected to close in early 27, and CFO Jon Monson warned that higher interest rates since the announcement will pressure the previously guided $0.06 to $0.08 of dilution. The balance sheet shows the strain: effective net cash of negative $10.2 billion, even after a $2 billion buyback in the July quarter.

Numbers versus narrative

The fundamentals do not yet show collapse. The July quarter delivered total revenue of $5.4 billion, up 8% year over year, with a gross margin of 70.7%. But that was before the cyber disruption hit Q3 and before the Q4 guide implied a decline. The company now expects full-year adjusted gross margin below 2025, full-year operating margin around 27.6%, and free cash flow of roughly $3.6 billion. The issue is not solvency — interest coverage is still 12.3x — it is credibility. Monson said it plainly: “we need to rebuild confidence in our forecast” — Jonathan Monson, Executive Vice President and Chief Financial Officer · 2026-10-28. When a management team says that, the market stops paying for the long-range plan and starts paying for proof. The proof points are specific: close Penumbra, stabilize WATCHMAN, get Ultra through design verification and validation, and show that urology can stop being a negative. Mahoney did not hide the execution problem: “We are not happy with some of these slips” — Michael F. Mahoney, Chairman and Chief Executive Officer · 2026-10-28. The cyber incident will fade; the share loss in EP will not until the product cadence improves. That is the difference between a bad quarter and a broken growth story. Right now, Boston Scientific is asking investors to believe 2028 before it has delivered 2027.